SCHEMBL6890137

SCHEMBL6890137

COC(=O)C(C)(C)NC(=O)N(CCO)CCC1CCCCC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 3/20 0.38
CNR1 P21554 1/20 0.38
CASR P41180 1/20 0.38
FKBP1A P62942 4/20 0.36
MMP3 P08254 1/20 0.35
MAPT P10636 2/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
ATM Q13315 1/20 0.34
ALDH1A1 P00352 3/20 0.33
MCHR1 Q99705 2/20 0.33
HRH3 Q9Y5N1 2/20 0.33
PPARA Q07869 4/20 0.32
PPARG P37231 3/20 0.32
TDP1 Q9NUW8 2/20 0.32
PPARD Q03181 2/20 0.32
GMNN O75496 1/20 0.32
USP2 O75604 1/20 0.32
USP1 O94782 1/20 0.32
LMNA P02545 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6895667 0.86 CXCR2 (0.37) CNR2CNR1CASRFKBP1AMAPT
SCHEMBL6898335 0.78 CNR1 (0.36) CNR2CNR1CASRFKBP1AALDH1A1
SCHEMBL6897927 0.75 EPHX1 (0.36) CASRFKBP1AMAPTMEN1KMT2A
SCHEMBL27538282 0.75 METAP2 (0.38) CASRFKBP1AKMT2AMCHR1HRH3
SCHEMBL27576386 0.75 METAP2 (0.38) CASRFKBP1AKMT2AMCHR1HRH3
SCHEMBL27538336 0.75 METAP2 (0.38) CASRFKBP1AKMT2AMCHR1HRH3
SCHEMBL27570927 0.74 PPARA (0.36) CASRMAPTALDH1A1PPARAPPARG
SCHEMBL27562663 0.73 METAP2 (0.37) CASRKMT2AALDH1A1MCHR1HRH3
SCHEMBL27562664 0.73 METAP2 (0.37) CASRKMT2AALDH1A1MCHR1HRH3
SCHEMBL1845894 0.73 CA14 (0.40) CASRMAPTMEN1KMT2AATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6730784-B2 AS THERAPEUTIC AGENTS FOR AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS SANTEN PHARMACEUTICAL CO., LTD. (JP) 2004-05-04 US disclosed
US-20020198376-A1 Novel urea derivatives SANTEN PHARMACEUTICAL CO., LTD. (JP) 2002-12-26 US disclosed
US-6492370-B1 Urea derivatives and pharmaceutical compositions thereof SANTEN PHARMACEUTICAL CO., LTD. (JP) 2002-12-10 US disclosed
EP-1072591-A1 NOVEL UREA DERIVATIVES SANTEN PHARMACEUTICAL CO., LTD. (JP) 2001-01-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020198376-A1 Novel urea derivatives TNF, CTH, CFH CNR2 383/4885CNR1 207/4885CASR 2206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.